17 August 2018
Visiongain’s new report Global Respiratory Diagnostics Market Report 2017-2027: Instruments & Devices, Assays & Reagents, Services & Software, Obstructive Sleep Apnoea (OSA) Diagnostics Tests, Imaging Diagnostic Tests, Traditional Diagnostic Tests, Molecular Diagnostic Tests, Other Tests, Tuberculosis, Asthma, Lung Cancer, COPD, Other Diseases, Hospitals, Reference Laboratories, Physician Offices, Other End-Users indicates that the global respiratory diagnostics market will see $8.00bn in spending in 2022.
The global respiratory diagnostics market is expected to grow at a CAGR of 7.1% in the first half of the forecast period. The market is expected to grow at a CAGR of 7.4% from 2017-2027. The market is estimated at $5.32bn in 2016 and $8.00bn in 2022. In 2016, The instruments and devices submarket held the largest market share at 57.7%, followed by the assays and reagents submarket at 23.8%.
The lead analyst of the report said: “The Asia-Pacific regional market is expected to grow at the fastest pace in the global market and is expected to offer significant growth opportunities for market players operating in the respiratory diagnostics market over the forecast period. Factors such as exponential rise in the geriatric population, rising per capita income, large investments in the healthcare industry by major market players, soaring demand for cutting-edge technologies, reduced labor costs, and favorable regulatory environment in various Asia-Pacific countries will fuel the growth of respiratory diagnostics market in these regions.”
The 197-page report contains 56 tables and 118 figures that add visual analysis in order to explain the developing trends within the Global Respiratory Diagnostics Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the global respiratory diagnostics market subdivided into product & service, test type, end-users and disease type.
The 197-page report offers market forecasts for the North America (the US and Rest of North America), Europe (the UK, Germany, France, Spain, Italy, Russia and Rest of Europe), Asia-Pacific (China, India, Japan, Rest of Asia-Pacific) and Rest of the World (Latin America, Middle East and Africa)
Moreover, our work discusses the leading companies in the respiratory diagnostics market. Our study discusses the drivers and restraints that affect the global respiratory diagnostics market. Our study also discusses Porter’s Five Forces analysis that influence the global respiratory diagnostics market
The report Global Respiratory Diagnostics Market Report 2017-2027: Instruments & Devices, Assays & Reagents, Services & Software, Obstructive Sleep Apnoea (OSA) Diagnostics Tests, Imaging Diagnostic Tests, Traditional Diagnostic Tests, Molecular Diagnostic Tests, Other Tests, Tuberculosis, Asthma, Lung Cancer, COPD, Other Diseases, Hospitals, Reference Laboratories, Physician Offices, Other End-Users report will be of value to anyone who wants to better understand the respiratory diagnostics market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the respiratory diagnostics market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.